Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Update: Adial Pharmaceuticals to Present at The 2019 Wall Street Conference

GlobeNewswire Thursday, 10 January 2019
CHARLOTTESVILLE, Va., Jan. 10, 2019 (GLOBE NEWSWIRE) -- *Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW)*, www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that William Stilley, President and Chief Executive Officer of Adial, will be presenting at the 2019 Wall Street Conference. The conference is by invitation only and will be held on Wednesday, January 16^th, 2019 at the Mar-a-Lago in Palm Beach, Florida and the presentation will be at 1:20 PM Eastern Standard Time.

The Wall Street Conference is one of the premiere conferences in the venture capital arena and small cap marketplace. Financial industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, attend the Wall Street Conference every year to discuss significant trends in emerging and growth industries.

*About Adial Pharmaceuticals, Inc.*

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (“AUD”). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.

*Contact:*

Crescendo Communications, LLC
David Waldman
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com
0
shares
ShareTweetSavePostSend
 

You Might Like


Tweets about this


Other recent news in Press Releases

Starr INSURANCE Offering Travel INSURANCE Through Facebook Messenger Chatbot in Hong KongDr. John P. Lederach, Professor Emeritus of University of Notre Dame, to Get 36th Niwano PEACE PRIZE
How To Customize The Best CAR INSURANCE Plan And Save MoneySeaside FLORIDA Vacation Rental Company Extends Dates of Spring Fever Travel Deal
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest